Invasive candidiasis is a disease of fungal etiology with an increasing incidence, specially in immunosuppressed patients (graft receivers, neutropenic and AIDS patients, etc), long-stay hospitalized and catheterized patients, as well as those subjected to extensive surgery or receiving broad spectrum antibiotic therapy. The diagnosis of invasive candidiasis is specially difficult due to the absence of pathognomonic symptoms specific of the disease and the low recovery of the microorganism in culture. The present commercial diagnostic techniques show a low specifity and sensitivity, being some of them too difficult to be carried out in a Clinical microbiology laboratory. In order to overcome these problems, a technique for the serologic diagnosis of invasive candidiasis has been developed. This test is based upon the detection of specific antibodies against antigens located on the cell wall surface of the mycelium of Candida albicans (CAGTA Candida albicans germ tube antibody). These antibodies are normally present in sera from patients with invasive candidiasis caused by C. albicans and other species of this genus. Detection methods based on chemiluminescence have received much attention due to their low background, linearity and wide dynamic range. When coupled to enzyme immunoassays, the signal amplification effect provided by the enzyme enables the design of CLIA (ChemiLuminescent ImmunoAssay) tests with shorter incubation times while keeping or improving their sensitivity.
Vircell
- це біотехнологічна компанія, що спеціалізується на розробці та виробництві готових до використання реагентів для інфекційних захворювань людини. Компанія присутня в лабораторіях понад 80 країн світу на п'яти континентах. Vircell пропонує понад 400 посилань на виявлення бактерій, вірусів, паразитів за допомогою різних методик: ІФА, хемілюмінесценція, пряма та непряма імунофлуоресценція, імунокаптаційна аглютинація, культура клітин та молекулярна біологія (олігохроматографія та контроль ПЛР).
Компанія Vircell, Гранада - Іспанія
